# BioNovoGene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bionovogene

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.panomix.com
- Total disclosed funding: $29M
- Latest round: Series A (Jun 28, 2023)
- Investors on record: 5

## About

Established in 2013 and based in Suzhou, China, BioNovoGene is a biopharmaceutical company that provides metabolomics technology services, clinical products and big data services. The company is led by talents from the "National Thousand Talents" program and Jinji Lake Science and Technology Leaders, and the core team come from Harvard University, MD Anderson Cancer Center and other universities and research institutes, covering a team of scientists in metabolomics and bioinformatics. By 2023, the company has provided metabolomics services to more than 400 research institutes, 400 tertiary hospitals and food and pharmaceutical companies in China and abroad. At the same time, the company has obtained the qualifications of CMA certified enterprise and high-tech enterprise, more than 30 intellectual property rights, and more than 20 clinically registered products. In June 2023, the company closed a round of series A+ funding.

The company's business segments include histology technology services, clinical mass spectrometry, histology clinical products and biological big data platform, covering metabolomics, proteomics testing services, clinical R&D and testing. Specific services include non-targeted metabolomics, targeted metabolomics, all-targeted, lipidomics, etc., covering more than 100 niche assays and analysis services. The company also has a cloud data analysis system, BioDeep, which provides a massive metabolite library and core matching algorithm support.

The company will use the series A+ funding to accelerate the development of a single-cell multi-omics technology platform.

## Funding rounds

- Series A, Jun 28, 2023, $14M — Oriza Holdings, YuanBio Venture, Leader Venture Capital
- Series A, Apr 29, 2021, $15M — YuanBio Venture
- Angel, Apr 9, 2018 — Watson Capital
- Seed, Jan 1, 2016 — Bohe Angel Fund

## Investors

- Bohe Angel Fund — Seed
- Watson Capital (https://capitalatlas.ai/funds/watson-capital) — Angel
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series A
- Leader Venture Capital (https://capitalatlas.ai/funds/leader-venture-capital) — Series A